海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300683 海特生物

已收盘 10-09 15:00:00

{"stockData":{"symbol":"300683","market":"SZ","secType":"STK","nameCN":"海特生物","latestPrice":26.43,"timestamp":1791529425000,"preClose":27.25,"halted":0,"volume":21021830,"delay":0,"changeRate":-0.0301,"floatShares":122000000,"shares":131000000,"eps":-2.0688,"marketStatus":"已收盘","change":-0.82,"latestTime":"10-09 15:00:00","open":25.5,"high":26.88,"low":24.2,"amount":531000000,"amplitude":0.0983,"askPrice":26.44,"askSize":168,"bidPrice":26.43,"bidSize":111,"shortable":0,"etf":0,"ttmEps":-2.0688,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":5,"adr":0,"adjPreClose":27.25,"symbolType":"stock","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":29.98,"lowLimit":24.53,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":130894391,"isCdr":false,"pbRate":1.71,"roa":"--","roe":"--","epsLYR":-1.77,"committee":-0.208099,"marketValue":3460000000,"turnoverRate":0.172,"status":1,"floatMarketCap":3230000000},"requestUrl":"/m/hq/s/300683/","defaultTab":"news","newsList":[{"id":"2673051766","title":"诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051766","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673051766?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:30","pubTimestamp":1791293401,"startTime":"0","endTime":"0","summary":"近日，2026 年诺贝尔生理学或医学奖正式揭晓，表彰科学家在光遗传学领域的开创性研究成果，这项颠覆性底层技术火速出圈，引爆资本市场与生物医药行业关注，带动脑科学、神经基因治疗赛道热度全面攀升。业内人士分析，本次诺奖权威背书，将大幅加速光遗传学技术的科研转化与产业普及，进一步兑现赛道价值。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20261006/32388712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300683","BK0012","BK0060","688767","BK0175","BK0239","BK0183","BK0188","BK0216","BK0096","BK0196","BK0236","301293","BK0187","BK0028","600196","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233503","title":"海特生物(300683.SZ)：注射用埃普奈明获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233503","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670233503?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:21","pubTimestamp":1790587278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海特生物(300683.SZ)发布公告，公司于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发的《药物临床试验批准通知书》(通知书编号：2026LP02967)，公司申报的注射用埃普奈明(商品名：沙艾特)临床试验申请已获得国家药监局批准，同意本品开展软骨肉瘤的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300683","BK0239","BMED","IBBJ","PSYK","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409693","title":"股市必读：海特生物(300683)股东户数1.9万户，较上期增加7.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409693","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409693?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:37","pubTimestamp":1790530627,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，海特生物报收于25.16元，下跌3.34%，换手率3.92%，成交量4.79万手，成交额1.22亿元。交易信息汇总资金流向9月24日主力资金净流出1243.12万元，占总成交额10.16%；游资资金净流出908.98万元，占总成交额7.43%；散户资金净流入2152.1万元，占总成交额17.58%。股本股东变化股东户数变动截至2026年9月18日公司股东户数为1.9万户，较8月31日增加1304.0户，增幅为7.38%。户均持股数量由上期的7406.0股减少至6897.0股，户均持股市值为17.29万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430584","title":"海特生物：截止9月18日，公司股东人数为18,978户","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430584?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:01","pubTimestamp":1790211677,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年9月20日公司的股东总数是多少？谢谢海特生物回复：您好，感谢您对公司的关注！截止9月18日，公司股东人数为18,978户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400008763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668496689","title":"997亿美元BD交易背后：CRO熬过寒冬，迎来供需反转时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668496689","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668496689?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:10","pubTimestamp":1789639801,"startTime":"0","endTime":"0","summary":"创新药出海全面爆发国产创新药出海持续提速，成为本轮CRO行业回暖的核心驱动力。渤海证券研报显示，2026年上半年我国创新药对外授权交易数量突破100笔，交易总金额达到997亿美元，交易规模创下历年同期新高，延续了2025年的高增长态势。临床CRO龙头泰格医药深度绑定国内创新药BD出海浪潮，国内多中心临床试验需求释放，作为临床CRO标杆企业，充分受益本土创新药研发回暖。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/17/20260917555605.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/17/20260917555605.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260917/32373302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300683","BK0239","BK1574","IBBQ","688137","300434","BK0046","BK1161","BK0102","BK0028","301520","BK0086","LNGR","BK0077","600721","BK0282","000504","BK0216","301047","MEDX","BK0042","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589201","title":"海特生物(300683)8月31日股东户数1.77万户，较上期减少7.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666589201?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:28","pubTimestamp":1788946133,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年8月31日公司股东户数为1.77万户，较8月20日减少1451.0户，减幅为7.59%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至8月31日，医疗服务行业平均股东户数为4.75万户。从股价来看，2026年8月20日至2026年8月31日，海特生物区间跌幅为15.64%，在此期间股东户数减少1451.0户，减幅为7.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530579","title":"海特生物：截止8月20日，公司股东人数为19,125户","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530579","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666530579?lang=zh_cn&edition=full","pubTime":"2026-09-09 09:06","pubTimestamp":1788915967,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司截至8月20日和8月底的股东人数分别是多少？海特生物回复：您好，感谢您对公司的关注！截止8月20日，公司股东人数为19,125户。截止8月31日，公司股东人数为17,674户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900008508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201321","title":"海特生物（300683）2026年中报简析：净利润同比下降100.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662201321?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:06","pubTimestamp":1787609211,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海特生物发布2026年中报。根据财报显示，海特生物净利润同比下降100.89%。截至本报告期末，公司营业总收入2.26亿元，同比下降18.01%，归母净利润-7870.71万元，同比下降100.89%。按单季度数据看，第二季度营业总收入6647.15万元，同比下降43.86%，第二季度归母净利润-5566.08万元，同比下降120.44%。本次财报公布的各项数据指标表现不尽如人意。融资分红：公司上市9年以来，累计融资总额17.46亿元，累计分红总额8523.06万元，分红融资比为0.05。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500009242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662720566","title":"股市必读：海特生物新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662720566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662720566?lang=zh_cn&edition=full","pubTime":"2026-08-25 03:20","pubTimestamp":1787599227,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年半年度报告摘要显示，营业收入同比下降18.01%，归属于上市公司股东的净利润为-78,707,087.58元，同比下降100.89%。公司公告汇总2026年半年度报告摘要证券代码：300683，证券简称：海特生物，公告编号：2026-036。2026年半年度报告及摘要披露提示性公告《2026年半年度报告》及其摘要已于2026年8月21日经第九届董事会第十次会议审议通过，并于2026年8月24日在巨潮资讯网披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500006344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224372","title":"破发股海特生物跌11.4% 国投证券保荐上市累募17.5亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224372","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224372?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:40","pubTimestamp":1787560805,"startTime":"0","endTime":"0","summary":"中国经济网北京8月24日讯 海特生物 今日收报25.78元，跌幅11.41%。目前该股处于破发状态。　　海特生物于2017年8月8日登陆创业板，上市发行新股共2583.88万股，发行价格为32.94元/股，募集资金总额8.51亿元，扣除发行费用后，公司实际募集资金净额为7.97亿元。　　海特生物上市以来三次募集资金共计17.46亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260824/32344879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300683","161027","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661984247","title":"A股CRO概念持续走弱，海特生物跌超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661984247","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661984247?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:38","pubTimestamp":1787539132,"startTime":"0","endTime":"0","summary":"8月24日，A股CRO概念持续走弱，海特生物跌超11%，泰格医药跌9.42%，义翘神州跌8.17%，近岸蛋白、奥浦迈、博腾股份跌超6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608243850854518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608243850854518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02846","07233","83130","02827","159982","83188","399300","BK0239","03188","03130","82846","BK1147","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661210098","title":"图解海特生物中报：第二季度单季净利润同比下降120.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661210098","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661210098?lang=zh_cn&edition=full","pubTime":"2026-08-23 17:27","pubTimestamp":1787477235,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物2026年中报显示，上半年度公司主营收入2.26亿元，同比下降18.01%；归母净利润-7870.71万元，同比下降100.89%；扣非净利润-8026.71万元，同比下降39.65%；其中2026年第二季度，公司单季度主营收入6647.15万元，同比下降43.86%；单季度归母净利润-5566.08万元，同比下降120.44%；单季度扣非净利润-5646.63万元，同比下降39.78%；负债率15.43%，投资收益-186.55万元，财务费用-177.89万元，毛利率34.25%。财报数据概要请见下图:本文数据来源于海特生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300008485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661521027","title":"海特生物(300683)8月10日股东户数1.89万户，较上期增加6.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661521027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661521027?lang=zh_cn&edition=full","pubTime":"2026-08-23 17:07","pubTimestamp":1787476048,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年8月10日公司股东户数为1.89万户，较6月30日增加1169.0户，增幅为6.61%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至8月10日，医疗服务行业平均股东户数为4.78万户。从股价来看，2026年6月30日至2026年8月10日，海特生物区间涨幅为16.63%，在此期间股东户数增加1169.0户，增幅为6.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300008075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993901","title":"海特生物：截止8月10日，公司股东人数为18,860户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993901?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:30","pubTimestamp":1786437037,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司最新的股东人数是多少？海特生物回复：您好，感谢您对公司的关注！截止8月10日，公司股东人数为18,860户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100025887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656153503","title":"海特生物：埃普奈明新产线建设已经完工","url":"https://stock-news.laohu8.com/highlight/detail?id=2656153503","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656153503?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:27","pubTimestamp":1785832030,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物08月04日在投资者关系平台上答复投资者关心的问题。埃普奈明新产线建设已经完工，后续还需认证和审批，不存在您提及延期和前后不一致的情形。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330555","title":"海特生物(300683.SZ)参股公司ZM-02眼用注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656330555?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:52","pubTimestamp":1785829957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海特生物 发布公告，近日，公司参股公司中眸医疗科技(武汉)有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的ZM-02眼用注射液临床试验申请已获得国家药品监督管理局批准，同意本品开展治疗晚期视网膜色素变性的临床试验。据悉，ZM-02是中眸医疗自主研发的新一代光遗传学基因疗法，用于治疗晚期视网膜退行性疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海特生物(300683.SZ)参股公司ZM-02眼用注射液获批开展临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656201533","title":"海特生物：参股公司ZM-02眼用注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656201533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656201533?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:48","pubTimestamp":1785829683,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653405700","title":"海特生物最新公告：注射用埃普奈明临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2653405700","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653405700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:54","pubTimestamp":1784883291,"startTime":"0","endTime":"0","summary":"海特生物(300683.SZ)公告称，公司申报的注射用埃普奈明(商品名：沙艾特)用于不可切除或转移的经典型软骨肉瘤适应症的临床试验申请获得国家药监局受理。该药品为公司自主研发的国家I类重组蛋白类创新药，是全球首个且唯一上市的死亡受体4/死亡受体5激动剂。目前，尚无针对软骨肉瘤适应症的药物获批上市，该药品研发周期长、风险较高，短期内对公司业绩不会产生实际影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453630","title":"海特生物：推进埃普奈明新产能扩建及新适应症拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453630","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651453630?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:21","pubTimestamp":1784103670,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物07月15日在投资者关系平台上答复投资者关心的问题。请问除了扩产，实体瘤拓展和MM一二线推进两者中，公司有无优先级海特生物回复：您好，感谢您对公司的关注。公司今年重点工作是推进埃普奈明新产能的扩建及新适应症的拓展。埃普奈明针对软骨肉瘤的新适应症研究，已申报正式注册临床，目前正在Pre-IND阶段，预计今年将开展正式临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650990174","title":"股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650990174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650990174?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:12","pubTimestamp":1783530731,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，海特生物报收于24.79元，下跌4.29%，换手率5.2%，成交量6.35万手，成交额1.61亿元。交易信息汇总资金流向7月8日主力资金净流出1379.64万元；游资资金净流出714.95万元；散户资金净流入2094.59万元。股本股东变化股东户数变动截至2026年6月30日，公司股东户数为1.77万户，较6月18日增加511.0户，增幅2.97%；户均持股数量由7619.0股减少至7399.0股，户均持股市值为18.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791579089343,"stockEarnings":[{"period":"1week","weight":0.0348},{"period":"1month","weight":0.081},{"period":"3month","weight":0.0197},{"period":"6month","weight":-0.2697},{"period":"1year","weight":-0.2199},{"period":"ytd","weight":-0.0469}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉海特生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18978人(较上一季度增加7.38%)","perCapita":"6439股","listingDate":"2017-08-08","address":"湖北省武汉市蔡甸区经济技术开发区海特科技园","registeredCapital":"13089万元","survey":"　　武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是注射用鼠神经生长因子、注射用埃普奈明、注射用磷酸特地唑胺、注射用盐酸罗沙替丁醋酸酯、己酮可可碱注射液、注射用艾司奥美拉唑钠、注射用帕瑞昔布钠、注射用硫酸艾沙康唑、原料药及中间体、药学研究、CRO临床业务。","listedPrice":32.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海特生物,300683,海特生物股票,海特生物股票老虎,海特生物股票老虎国际,海特生物行情,海特生物股票行情,海特生物股价,海特生物股市,海特生物股票价格,海特生物股票交易,海特生物股票购买,海特生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}